定量[18F]florbetapir PET/CT或可识别系统性AL淀粉样变性肺部受累
前瞻性纳入58例活检证实的系统性AL淀粉样变性患者和9例对照,评估肺[18F]florbetapir摄取。视觉分析显示69%的AL患者无肺摄取,12%表现为强烈双侧均匀摄取;定量参数Vs、TBR、RI在该组显著高于对照。无视觉肺摄取的AL患者Vs仍较对照高3倍以上。
要点
- 定量[18F]florbetapir PET/CT可无创识别肺AL淀粉样变性。
- 视觉无肺摄取的AL患者Vs仍高于对照,提示亚临床沉积可能。
- 强烈肺摄取与心脏AL沉积标志物LV SUVmax独立相关。
核心结论
- [18F]florbetapir PET/CT有潜力无创识别肺AL淀粉样变性,其临床相关性需进一步研究。
研究设计与样本
- 前瞻性纳入58例活检证实的系统性AL淀粉样变性患者和9例对照(5例无淀粉样变性,4例ATTR心脏淀粉样变性)。
- 通过视觉分析和定量参数Vs(分布容积)、SUVmax、RI(保留指数)、TBR(靶血比)评估肺[18F]florbetapir摄取。
主要发现
- 视觉分析中,69%(40/58)的AL患者无肺示踪剂摄取,12%(7/58)表现为强烈双侧均匀摄取。
- 强烈肺摄取组较对照组Vs中位数高30倍(9.79 vs 0.26,p<0.001),TBR中位数12.0 vs 1.71(p<0.001),RI中位数0.310 vs 0.033(p<0.001)。
- 无视觉肺摄取的AL组Vs中位数仍较对照组高3倍以上(0.99 vs 0.26,p<0.001)。
- Vs与左心室SUVmax(心脏AL沉积标志物)独立相关,但与射血分数(心脏功能障碍标志物)无关。
- 强烈肺[18F]florbetapir摄取与[11C]acetate肺摄取无关,提示其代表AL淀粉样变性而非心力衰竭。
临床怎么用
- 定量[18F]florbetapir PET/CT可用于系统性AL淀粉样变性患者肺受累的无创评估。
- 视觉阴性患者仍可能存在定量Vs升高,需结合定量参数综合判断。
局限性
- 结论指出[18F]florbetapir PET/CT识别肺AL淀粉样变性的临床相关性仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The clinical diagnosis of pulmonary involvement in individuals with systemic AL amyloidosis remains challenging. [18F]florbetapir imaging has previously identified AL amyloid deposits in the heart and extra-cardiac organs. The aim of this study is to determine quantitative [18F]florbetapir pulmonary kinetics to identify pulmonary involvement in individuals with systemic AL amyloidosis. METHODS: We prospectively enrolled 58 subjects with biopsy-proven AL amyloidosis and 9 control subjects (5 without amyloidosis and 4 with ATTR cardiac amyloidosis). Pulmonary [18F]florbetapir uptake was evaluated visually and quantified as distribution volume of specific binding (Vs) derived from compartmental analysis and simpler semiquantitative metrics of maximum standardized uptake values (SUVmax), retention index (RI), and target-to-blood ratio (TBR). RESULTS: On visual analysis, pulmonary tracer uptake was absent in most AL subjects (40/58, 69%); 12% (7/58) of AL subjects demonstrated intense bilateral homogeneous tracer uptake. In this group, compared to the control group, Vs (median Vs 30-fold higher, 9.79 vs. 0.26, p < 0.001), TBR (median TBR 12.0 vs. 1.71, p < 0.001), and RI (median RI 0.310 vs. 0.033, p < 0.001) were substantially higher. Notably, the AL group without visually apparent pulmonary [18F]florbetapir uptake also demonstrated a > 3-fold higher Vs compared to the control group (median 0.99 vs. 0.26, p < 0.001). Vs was independently related to left ventricular SUVmax, a marker of cardiac AL deposition, but not to ejection fraction, a marker of cardiac dysfunction. Also, intense [18F]florbetapir lung uptake was not related to [11C]acetate lung uptake, suggesting that intense [18F]florbetapir lung uptake represents AL amyloidosis rather than heart failure. CONCLUSIONS: [18F]florbetapir PET/CT offers the potential to noninvasively identify pulmonary AL amyloidosis, and its clinical relevance warrants further study.
引用
- Khor YM, Cuddy S, Harms HJ, et al. Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging. 2019. PMID: 31807884. doi:10.1007/s00259-019-04627-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。